D
Daewoong Pharmaceutical A069620
Last Price
52 Week Range
₩109.00K - ₩199.40K
Next Earnings Date
Feb 09 2026 (Estimate)
Next Earnings Date
Feb 09 2026 (Est.)
Last Price
Balance Sheet
| Metric | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | LTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₩137.685B | ₩116.347B | ₩208.62B | ||||||||||||||||||
| ₩184.007B | ₩214.726B | ₩223.93B | ||||||||||||||||||
| ₩241.545B | ₩256.353B | ₩312.356B | ||||||||||||||||||
| ₩14.48B | ₩23.789B | ₩2.401B | ||||||||||||||||||
| ₩-2.893B | ₩1.577B | ₩42.2B | ||||||||||||||||||
| ₩574.824B | ₩612.792B | ₩789.507B | ||||||||||||||||||
| ₩521.919B | ₩675.666B | ₩762.918B | ||||||||||||||||||
| ₩297.485B | ₩346.71B | ₩371.201B | ||||||||||||||||||
| ₩292.384B | ₩167.306B | ₩245.995B | ||||||||||||||||||
| ₩71.304B | ₩68.786B | ₩81.953B | ||||||||||||||||||
| ₩12.394B | ₩105.717B | ₩8.931B | ||||||||||||||||||
| ₩1.195T | ₩1.364T | ₩1.471T | ||||||||||||||||||
| - | - | - | ||||||||||||||||||
| ₩1.77T | ₩1.977T | ₩2.261T |
| Metric | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | LTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₩220.756B | ₩210.6B | ₩130.822B | ||||||||||||||||||
| - | - | - | ||||||||||||||||||
| ₩369.191B | ₩321.495B | ₩309.319B | ||||||||||||||||||
| ₩1.194B | ₩2.002B | ₩1.209B | ||||||||||||||||||
| ₩14.497B | ₩11.328B | ₩21.043B | ||||||||||||||||||
| - | - | - | ||||||||||||||||||
| ₩35.18B | ₩95.319B | ₩242.55B | ||||||||||||||||||
| ₩626.322B | ₩629.416B | ₩683.9B | ||||||||||||||||||
| ₩63.678B | ₩323.203B | ₩480.499B | ||||||||||||||||||
| ₩2.516B | ₩3.276B | ₩2.2B | ||||||||||||||||||
| ₩39.807B | ₩33.65B | ₩6.586B | ||||||||||||||||||
| ₩5.009B | ₩3.53B | ₩3.499B | ||||||||||||||||||
| ₩50.74B | ₩57.645B | ₩79.91B | ||||||||||||||||||
| ₩162.497B | ₩420.577B | ₩572.477B | ||||||||||||||||||
| ₩69.211B | - | - | ||||||||||||||||||
| ₩0.858T | ₩1.05T | ₩1.256T |
| Metric | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | LTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₩-2.85B | ₩-2.85B | ₩-2.85B | ||||||||||||||||||
| - | - | - | ||||||||||||||||||
| ₩28.966B | ₩28.966B | ₩28.966B | ||||||||||||||||||
| ₩647.835B | ₩-4.077B | ₩734.737B | ||||||||||||||||||
| ₩158.347B | ₩149.814B | ₩149.195B | ||||||||||||||||||
| ₩-26.852B | - | - | ||||||||||||||||||
| - | ₩622.786B | ₩-30.195B | ||||||||||||||||||
| ₩802.975B | ₩794.64B | ₩879.854B | ||||||||||||||||||
| ₩144.978B | ₩132.345B | ₩124.274B | ||||||||||||||||||
| ₩912.281B | ₩926.985B | ₩879.854B | ||||||||||||||||||
| ₩1.77T | ₩1.977T | ₩2.136T |
| Metric | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | LTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₩318.562B | ₩180.703B | ₩250.353B | ||||||||||||||||||
| ₩436.707B | ₩649.249B | ₩793.009B | ||||||||||||||||||
| ₩419.491B | ₩546.299B | ₩588.748B |
Balance Sheet Composition
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.